Yuichi Ando

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Advanced Non Small Cell Lung Cancer

Top Venues

Japanese journal of clinical oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Yao Liang, Osamu Maeda, Yuichi Ando
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Japanese journal of clinical oncology (2024)
Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando
Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PloS one 19 (7) (2024)
Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando
Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PloS one 19 (7) (2024)
Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando
Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. PloS one 19 (7) (2024)
Yao Liang, Osamu Maeda, Yuichi Ando
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Japanese journal of clinical oncology 54 (4) (2024)
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Katsuhiko Naoki, Tetsuhiko Asao, Kazuhisa Takahashi, Sho Saeki, Takuro Sakagami, Kazuhisa Nakashima, Yukari Tsubata, Yu Fujita, Kazuyoshi Kuwano, Megumi Furuta, Jun Sakakibara Konishi, Mayu Ohuchi, Yuichi Ando, Hidenori Mizugaki, Akinobu Hamada
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical pharmacology and therapeutics (2024)
Yuichi Ando, Tomohiro Terada
Consent in Pharmacogenetic Testing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Osamu Maeda, Masahide Fukaya, Masahiko Koike, Kazushi Miyata, Mitsuro Kanda, Kazuki Nishida, Masahiko Ando, Yasuhiro Kodera, Yuichi Ando
Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study. Asia-Pacific journal of clinical oncology 18 (6) (2022)
Yuichi Ando, Sachi Morita, Tomoya Shimokata, Toyonori Tsuzuki, Shigeru Inafuku, Kenichiro Iwami, Nicoletta Brega, Takashi Akagawa, Toshiaki Tsujino, Tetsuya Ogawa
A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal. International cancer conference journal 11 (4) (2022)
Hironobu Minami, Naomi Kiyota, Shiro Kimbara, Yuichi Ando, Tomoya Shimokata, Atsushi Ohtsu, Nozomu Fuse, Yasutoshi Kuboki, Toshio Shimizu, Noboru Yamamoto, Kazuto Nishio, Yutaka Kawakami, Shin-Ichi Nihira, Kazuhiro Sase, Takahiro Nonaka, Hideaki Takahashi, Yukiko Komori, Koshin Kiyohara
Guidelines for clinical evaluation of anti-cancer drugs. Cancer science 112 (7) (2021)
Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Staal Rohrberg, Sant P Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P Steinbach, Michael C Burger, Katharina Johanna Wenger, Ulrik N Lassen, Kamalesh K Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuss, Charles Cai, Eleni Lagkadinou, Michael Jeffers, Carol Peña, Ghazaleh Tabatabai
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Osamu Maeda, Tomoya Shimokata, Yuichi Ando
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (14) (2021)
Yoshihiro Nishida, Shunsuke Hamada, Hiroshi Urakawa, Kunihiro Ikuta, Tomohisa Sakai, Hiroshi Koike, Kan Ito, Ryo Emoto, Yuichi Ando, Shigeyuki Matsui
Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial. Cancer science 111 (11) (2020)
Hironobu Minami, Toshihiko Doi, Masanori Toyoda, Yoshinori Imamura, Naomi Kiyota, Ayako Mitsuma, Tomoya Shimokata, Yoichi Naito, Nobuaki Matsubara, Takeshi Tajima, Kota Tokushige, Kae Ishihara, Scott Cameron, Yuichi Ando
Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies. Cancer science 112 (2) (2020)
Kan Yonemori, Makoto Kodaira, Taroh Satoh, Toshihiro Kudo, Shunji Takahashi, Kenji Nakano, Yuichi Ando, Tomoya Shimokata, Joji Mori, Koichi Inoue, Gerard J Oakley, Sachi Sakaguchi, Kenji Tamura
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma. Cancer science 109 (12) (2019)
Yuichi Ando, Satoru Iwasa, Shunji Takahashi, Hideo Saka, Tomoyuki Kakizume, Kazuto Natsume, Naoko Suenaga, Cornelia Quadt, Yasuhide Yamada
Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer science 110 (3) (2019)